Member Info for Vander

Https://www.nature.com/articles/s41408-026-01544-5

Has Peter fowler stepped down also?

Michael Wyler has been appointed as chairman

As per David Brent: the bad news is that Wsg have delisted and you guys have lost your money. The good news is that I am promoted to ceo and chairman.

So…silver lining’

Fowler announced over 60 MOUs none of which he was able to progress to MSCs. He stoked false excitement to support repeated placings

He is an experienced operator and gulled new investors into half baked schemes, using his role as senior security officer as a mask for honesty and respectability. His claims were amplified by some knowing posters on here

He also used the cloak of client confidentiality to hide the location of proposed MSc eg Iran, which he continued to promote after trump had been in office for a year

In recent years he has achieved contracts which unexecuted eg sw Africa, unexchanged eg Iran, aborted on announcement eg Liberia, unprogressed eg DRC or unsustainable eg tema, ferry and now unpaid eg Lungi and Gabon

Fowler is narcissistic to the core, and will blame, distract and withhold information but claim generous recompense for himself and family

It’s surprising how he has been able to get away with it for so long and may continue to do so- unfortunately the nomad and bod facilitated him - until the end

Isnt fowler going to keep the company going with Greystoke riding shotgun?

Balders was weighing them down- those guys can now really motor

Fowler has been ok at operations and growing revenues

Hopeless at making a profit and grossly dishonest in persuading gullible SHs (and now mr pantheon) to pay for his half arsed gambles and the fowler family lifestyle.

He is going to get away with it, and he is not reflective enough to acknowledge SHs losses and his own dishonesty. It’s ironic that he finally achieved some success with Gabon, but he hasn’t been paid, and the cash flow is too fragile to cope

I believe fowler thinks he is great however

Fowler has consolidated his power and aligned with Greystoke- baldry and the Ned were summarily ejected

We are approaching a moment of judgement

Fowler may secure a new nomad and necessary funding- he is working hard to achieve this. Was he upfront about the underlying financial difficulties/non payment of MSC monies? I may have missed it

Beyond that we can make a final reflection on his tenure as CEO of a listed company

Ai estimates remain listed 40-55%

Fowler to remain in control as he is aligned with pantheons non dilutive aims, and they don’t want day to day operation Al headaches. New nomad possible as Gabon payments back online in May 26

In the wind up party I wonder if they will go to Ramaswamy and fowler can pose for some individual photos or on the margins of the table with some dignitaries

Also he can punch the air with the paperwork as he did in the DRC contract signing meeting, whilst onlookers look at the floor in embarrassment

He said he wouldn’t sell his shares for less than a pound? Hhmmm…Not the greatest judgement

Some of our have had a long term relationship with fowler with his many pompous RNS promising such an exciting future, which he was always on the cusp of delivering. Some on here repeatedly pasted his MOUs and contracts, encouraging newbies and the gullible to invest, and pointing out the inaccuracies of the naysayers. There are some dim witted staunch loyalists here even now, but also some clever predators. Fowler has no respect for LTHs who he sees as mugs who fund him and his family- he’s grateful for our largesse but see ya! (Punch the air). A classic scam is the invitation to buy a Nigerian bridge- at bargain price- this has been similar

The publication of individual patient data as a market update is nonsensical and prone to bias and chance-the lowest dose has however been safe and viable to continue the trial- the results haven’t been so good to prompt accelerated trial status or big pharma acquisition as others predicted.

Some of Vlad’s timelines are over optimistic -especially on manufacturing- also do you see them recruiting one patient per month?? It’s likely they will proceed at the same rate as other similar trials - 4 ppts per year? 12 ppts in 3 years? Commercialisation is more likely if it’s safe at that stage with at least some efficacy

No one predicted the Aim suspension- but the updates on Gabon and SL airport security fee reductions were prescient

We know that fowler’s explanation of time constraints as the cause of the delayed accounts was untrue (given the passage of time since)

The future depends on demonstration of new revenue eg gabon, providing a succour for the past

Alternatively there may be significant change or an abrupt end- fowler may slink off with defiance, no explanations or remorse- congratulating himself on a job well done. It’s ok- if he were apologetic it would be even worse

If fowler uses this hiatus to engineer his exit, would punters be surprised or sad?

Balders may also leave and possibly the other fowlers

Fowlers grand visions will not have come to pass and disappointedly a competent and honest replacement will not be able to recreate them

Btw mr pantheon liquidated Abercorn school at short notice. He is not afraid to make tough decisions and upset stakeholders- have a look at the parents bb

Use of aim suspension has a temporary haven- Mr pantheon may have widened fowler’s repertoire

Fowler should address the Ecowas directive of 25% reduction in security fee, which SLAA has also committed to in 2026- and how they make the cost saving. Something similar may ultimately apply in Gabon.

The majority of early stage CAR Tcell trials are Chinese investigator lead studies

There is an interesting AI search to be had here and the implications of this. They can reach proof-of-concept and partnerships quickly, but they usually face a second, longer development cycle before they can be commercialised globally. They rely on local manufacture (not global GMP), and these early trials may not meet standards to be accepted by FDA/EMA

There is a lot of detail on different targets especially CLL-1, CD33, CD123, FLT3 etc

Multiple early phase FLT3 CAR-T trials from:

Soochow University

Wuhan Union Hospital

PersonGen Biotherapeutics

Dose Levels Dose level 1: 7x10^7 Transduced CAR+ HG-CT-1 Dose level 2: 1.4x10^8 Transduced CAR+ HG-CT-1 Dose level 3: 3.5x10^8 Transduced CAR+ HG-CT-1 If Dose level 1 is found not to be safe, dose will be de-escalated to 3.5 x 10^7 Transduced CAR+ HG-CT-1

The cd7 trial used the below, with higher first dose:

Patients received a single infusion of CAR+ T cells at doses of 2×10⁸ (n=3), 4×10⁸ (n=3) or 0.9-1×10⁹ (n=4) CAR+ T cells.

No differentiation in expansion, max, efficacy or AEs by dose level in the abstract.

Https://ashpublications.org/blood/article/146/Supplement%201/816/554932/CD7-targeted-universal-CAR-T-cell-therapy-in

Interesting 10 patient phase 1 study for CD7 subset (approx 30%) r/r AML. Better tolerated than the pan myeloid antigens (no DLTs) with overall response rate 50% and mean durability of 10.1 months- seen as an alternative to myeloablation prior to HSCT (in the cd7 subgroup).

Vlad estimated a ‘slight’ trial delay due to made transfer and hoped for a much higher throughput of patient approx one per month in the adult trial- although he did make allowances for delays due to unavoidable management of side effects for individual patients

However, efficient logistics needs the back up of a big company with a lot of staff, funding and well worked through SoPs, with dedicated time to liaise with on the ground clinicians/ manufacturers

It was marketed for offers over £1.25m- 8 months ago